Home » Healthcare » Pharmaceuticals » Botulinum Toxin Market

Botulinum Toxin Market By Product Type (Botulinum Toxin A (BNT-A), Botulinum Toxin B (BNT-B)), By Application (Cosmetics, Neurological Disorders, Other Therapeutic Areas), By End User (Hospitals, Dermatology & Beauty Clinics, Spas & Cosmetic Centers) – Growth, Future Prospects & Competitive Analysis, 2018 – 2026

Summary
Table Of Content

Botulinum Toxin Market to Exhibit Profitable Growth during the Forecast Period

The global botulinum toxin market was expanding rapidly and was worth $4,228.2 million in 2017. The major factors driving the overall growth of the global botulinum toxin market are growing cosmetic and surgical procedures, treatment with botulinum toxin A (BNT-A) for various therapeutic procedures, a growing population aged 25 to 60 years, and a growing demand for minimally invasive procedures. Furthermore, new technological advancements in Botox injections and drugs for the treatment of glabellar lines, lower and upper limb spasticity, cervical dystonia, and blepharospasm are generating significant revenue in developed markets. Furthermore, favorable private and public initiatives in the medical sector across various developing countries, product expansion, and an increasing number of dermatology and beauty clinics with higher acceptance of branded botulinum products will further assist in the overall growth of the botulinum toxin market.

The BNT type A segment was leading the global market in 2017; numerous BNT type A products are commercially available in the domestic and international markets, which include top leading brands such as Botox, Xeomin, and Dysport. Increasing awareness and broad utilization of BNT types A and B in the treatment of cosmetic and therapeutic applications such as forehead lines, crow’s feet, square jaw/masseter, frown lines/glabellar, cervical dystonia, and others are going to spur further revenue growth during the forecast period.

In the last decade, increased R&D efforts have broadened the use of Botox across a variety of cosmetic indications. Allergan’s BNT received U.S. FDA approval for the treatment of hyperhidrosis in 2004; later in 2009, it got officially approved for cervical dystonia; in 2010 for post-stroke upper limb spasticity and urinary incontinence; in 2011 for overactive bladder; and in 2017, the U.S. FDA approved BNT for the treatment of lower limb spasticity in adults. Technological developments in botulinum toxin, both in invasive and noninvasive treatment procedures, are boosting the demand, primarily in the Asia Pacific and Europe.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Synopsis

The Botulinum Toxin Type A (BNT A) Segment is Expected to Register Higher Growth by 2026.

In the past decade, various studies and research have shown that the regular history of neurological disorders can be emphatically influenced by non-operative treatment, particularly Botox. Different types of treatment, such as smoothing of facial wrinkles, chronic migraine, blepharospasm (uncontrollable blinking), severe underarm sweating, strabismus (misaligned eyes), and overactive bladder by botulinum toxin, will gain traction during the forecast period.

Increasing noninvasive aesthetic rejuvenation procedures are going to spur revenue growth in the global market. Increased preference for noninvasive procedures, minor complications after surgery, rising approval for cosmetic surgeries such as facelifts and liposuction, and the growing importance of medical aesthetics globally are all factors contributing to maximizing revenue growth. However, a few complications that may occur, such as physiological disturbance, potential health risk, low awareness about botulinum toxins, skin color change, and post-surgery complications after a period of time, may act as a restraint during the forecast period.

Other issues, such as high treatment costs, less adoption of branded products, use of high-risk local products, and a lack of awareness about cosmetic and therapeutic applications in a few developing countries, may act as restraints during the forecast period.

Cosmetics in the Application Segment Expected to Register Higher Growth

The improvement of medications for the treatment of spasticity issues such as wrinkles will increase the competitiveness of manufacturers in the international market. Allergan, Merz Pharma, and Ipsen are currently occupying the maximum revenue share in the market. In the coming years, the demand for anti-aging treatments is expected to drive the uptake of cosmetic procedures. Additionally, there is an increase in demand for noninvasive solutions in cosmetology due to the lower possibility of complications post-surgery. Other external factors driving the cosmetics segment include growing awareness regarding physical appearance, new applications in cosmetics and aesthetics, FDA approval for new botulinum toxins, and demand for branded products in beauty and dermatology clinics in developed and developing nations.

The Hospitals and Clinics Segment Will Register Higher Growth

Since 1967, botulinum toxin A has been utilized for clinical purposes, and its efficacy and safety are well established globally. In 1980, botulinum toxin was first used for the treatment of strabismus (misaligned eyes) by infusing toxin into intraocular muscles as a contrasting option to strabismus surgical procedures. Although botulinum toxin was first officially approved by the US Food and Drug Administration in 1989 for the treatment of strabismus, blepharospasm, and hemiplegia, there has been a wide range of clinical and cosmetic utilization in the end-user segment since then.

According to the American Society of Plastic Surgeons, approximately US$ 16.4 billion was spent on cosmetic procedures in the United States in 2016. Also, in 2017, more than 7 million botulinum injections were utilized in the U.S. for overall cosmetic procedures. The growing number of aesthetic and cosmetic procedures in hospitals, dermatology clinics, and beauty centers with botulinum toxin, along with increasing approved applications for BNT types A and B, is expected to drive the overall growth of the botulinum toxin market during the forecast period. In 2014, Allergan Inc. received approval for BOTOX from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K. In 2016, Ipsen S.A. received U.S. FDA approval for its Dysport (abobotulinumtoxinA) injection indicated for the treatment of pediatric lower limb spasticity in children aged two years and older. In June 2017, the U.S. FDA approved the same botulinum toxin for the treatment of lower limb spasticity in adults. As indicated by the WHO, usage of commercially available Botox is high, and there has been an upsurge in cosmetic procedures worldwide in the past decade among the end-user segment.

The rising prevalence of scoliosis, combined with minimally invasive procedures and the presence of established players, keeps North America in the lead.

North America spearheaded the market in 2017 owing to the presence of established players along with increasing cosmetic and therapeutic procedures in the U.S. For instance, in 2016, as indicated by a report published by the American Society of Plastic Surgeons, around 7 million noninvasive cosmetic procedures were performed with Botulinum Type A (Botox, Xeomin, and Dysport), and there was an expansion of 4% in techniques as compared with 2015. Expanding the number of treatment techniques with botulinum toxin alongside rising approvals from the U.S. FDA is relied upon to drive the development of the worldwide botulinum toxin market. The rising trend of cosmetic procedures in the U.S. is also gaining momentum in the North American market on the global front.

Moreover, Asia Pacific will indicate fast development in the global botulinum toxin market, attributable to expanding R&D and the approval of novel BNT products in China. For example, in January 2018, Daewoong Pharmaceutical Co. Ltd., a Korean organization, got approval from Chinese experts to conduct clinical trials for the botulinum toxin Nabota in China. Additionally, the high adoption of BNT in cosmetics, an increase in acceptance of international brands in developing nations, technology assessment with approvals for BNT, growing demand for noninvasive therapies and procedures, and high awareness of new product applications are expected to drive the market for botulinum toxin during the forecast period.

Dominance of Established Multinational Players with Strong Product Portfolios Makes Market Penetration Difficult for Emerging Players

Major players in the botulinum toxin market are Allergan plc, Merz Pharma GmbH & Co. KGaA, Daewoong Pharmaceutical Co., Ltd., HUGEL, Inc., Hugh Source (International) Ltd., Medytox, Inc., US Worldmeds, LLC, Ipsen Group, Revance Therapeutics, Inc., and others. These manufacturers are implementing growth strategies such as partnerships with drug and medical technology companies, new technology assessments, and swift FDA approvals for new therapeutic and cosmetic treatments. Mergers and acquisitions can be seen by top firms as increasing economic benefits in a few regions. For instance, in 2017, Allergan received U.S. FDA approval for BOTOX Cosmetic (OnabotulinumtoxinA) for a novel indication in reducing forehead lines. Formerly, the same product had been approved for the management of glabellar lines and crow’s feet. In June 2017, the U.S. FDA also approved botulinum toxin for the treatment of lower limb spasticity in adults.

Periods of History and Forecast

This study report includes an analysis for each segment from 2016 to 2026, with 2017 as the base year. The compound annual growth rate (CAGR) for each of the respective segments is estimated for the forecast period from 2018 to 2026.

Report Scope by Segments

The botulinum toxin market comprises current market trends and dynamics along with a quantitative analysis of the global market. The report elucidates thorough information about the global botulinum toxin market by segmenting the market in terms of product, application, end-user, and geography. This report will assist healthcare professionals and market participants in making decisions and strategizing market positions.

The report also encompasses qualitative market assessment factors such as market trends, key market drivers, restraints, and opportunities that give a better understanding of the overall botulinum toxin market. Furthermore, the report also comprises a graphical representation of the competitive landscape based on their market initiatives and strategies, product portfolios, and business strengths.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

What are the current market trends and dynamics in the global botulinum toxin market, and what are the valuable opportunities for emerging players?
What is the market positioning of the key players operating in the market?
Which segment accounts for the fastest CAGR during the forecast period?
Which end-user holds a larger market share and why?
What is the impact of the high cost of cosmetic treatments on the botulinum toxin market?
Are low- and middle-income economies investing in the botulinum toxin market?
What are the market trends and dynamics in emerging markets such as Japan, Latin America, the Middle East, and Africa?

Chapter 1. Preface
1.1. Report Scope and Description
1.2. Research Methodology
1.2.1. Phase I-Secondary Research
1.2.2. Phase II-Primary Research
1.2.3. Phase III-Expert Panel Review
1.2.4. Assumptions
1.2.5. Approach Adopted
1.3. Market Segmentation

Chapter 2. Executive Summary
2.1. Global BT Market Portraiture
2.2. Global BT Market, By Product Type, 2017 (US$ Mn)
2.3. Global BT Market, By Application, 2017 (US$ Mn)
2.4. Global BT Market, By End User, 2017 (US$ Mn)
2.5. Global BT Market, by Geography, 2017 Vs 2026 (Value %)

Chapter 3. Global Botulinum Toxin (BT) Market: Market Dynamics and Future Outlook
3.1. Market Overview
3.2. BT: Future Trends
3.3. Current Scenario: Strategies Used for Drug Delivery Across BBB Drivers
3.4. Challenges
3.5. Opportunities
3.6. Attractive Investment Proposition, by Geography, 2017
3.7. Major Agreements, Partnerships and Collaborations
3.8. Competitive Landscape
3.8.1. Competitive Landscape, by Key Players, 2017

Chapter 4. Global Botulinum Toxin (BT) Market, by Product Type, 2016 – 2026 (US$ Mn)
4.1. Overview
4.2. BT A (BNT-A)
4.3. BT B (BNT-B)

Chapter 5. Global Botulinum Toxin (BT) Market, By Application, 2016 – 2026 (US$)
5.1. Overview
5.2. Cosmetics
5.3. Neurological Disorders
5.4. Other Therapeutic Areas

Chapter 6. Global Botulinum Toxin (BT) Market, By End User, 2016 – 2026 (US$)
6.1. Overview
6.2. Hospitals
6.3. Dermatology & Beauty Clinics
6.4. Spas & Cosmetic Centers

Chapter 7. Global Botulinum Toxin (BT) Market, by Geography, 2016 – 2026 (US$ Mn)
7.1. Overview
7.2. North America BT Market Analysis, 2016 – 2026
7.2.1. North America BT Market, By Product Type, 2016 – 2026 (US$ Mn)
7.2.2. North America BT Market, By Application, 2016 – 2026 (US$ Mn)
7.2.3. North America BT Market, By End User, 2016 – 2026 (US$ Mn)
7.2.4. North America BT Market, by Country, 2016 – 2026 (US$ Mn)
7.2.4.1. U.S.
7.2.4.2. Canada
7.3. Europe BT Market Analysis, 2016 – 2026
7.3.1. Europe BT Market, By Product Type, 2016 – 2026 (US$ Mn)
7.3.2. Europe BT Market, By Application, 2016 – 2026 (US$ Mn)
7.3.3. Europe BT Market, By End User, 2016 – 2026 (US$ Mn)
7.3.4. Europe BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
7.3.4.1. U.K.
7.3.4.2. Germany
7.3.4.3. Rest of Europe
7.4. Asia Pacific BT Market Analysis, 2016 – 2026
7.4.1. Asia Pacific BT Market, By Product Type, 2016 – 2026 (US$ Mn)
7.4.2. Asia Pacific BT Market, By Application, 2016 – 2026 (US$ Mn)
7.4.3. Asia Pacific BT Market, By End User, 2016 – 2026 (US$ Mn)
7.4.4. Asia Pacific BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
7.4.4.1. Japan
7.4.4.2. China
7.4.4.3. Rest of APAC
7.5. Latin America BT Market Analysis, 2016 – 2026
7.5.1. Latin America BT Market, By Product Type, 2016 – 2026 (US$ Mn)
7.5.2. Latin America BT Market, By Application, 2016 – 2026 (US$ Mn)
7.5.3. Latin America BT Market, By End User, 2016 – 2026 (US$ Mn)
7.5.4. Latin America BT Market, by Country/Region, 2016 – 2026 (US$ Mn)
7.5.4.1. Brazil
7.5.4.2. Mexico
7.5.4.3. Rest of Latin America
7.6. Middle East & Africa (MEA) BT Market Analysis, 2016 – 2026
7.6.1. MEA BT Market, by Product Type, 2016 – 2026 (US$ Mn)
7.6.2. MEA BT Market, By Application, 2016 – 2026 (US$ Mn)
7.6.3. MEA BT Market, By End User, 2016 – 2026 (US$ Mn)
7.6.4. MEA BT Market, by Region, 2016 – 2026 (US$ Mn)
7.6.4.1. GCC
7.6.4.2. Rest of MEA

Chapter 8. Company Profiles
8.1. Allergan Plc.
8.1.1. Business Description
8.1.2. Financial Information (Subject to data availability)
8.1.3. Product Portfolio
8.1.4. Key Developments
8.2. Speywood Pharmaceuticals
8.3. Merz Pharma GmbH & Co. KGaA
8.4. Elan Pharmaceuticals
8.5. Revance Therapeutics, Inc.
8.6. Medytox, Inc.
8.7. US Worldmeds,LLC
8.8. Lanzhou Institute of Biological Products Co.Ltd.
8.9. Ipsen Group

List of Figures

FIG. 1 Global Botulinum Toxin (BT) Market: Research Methodology
FIG. 2 Market Size Estimation – Top Down & Bottom up Approach
FIG. 3 Global BT Market Segmentation
FIG. 4 Global BT Market, by Product Type, 2017 (US$ Mn)
FIG. 5 Global BT Market, By Application, 2016 – 2026 (US$ Mn)
FIG. 6 Global BT Market, by End User, 2017 (US$ Mn)
FIG. 7 Global BT Market, by Geography, 2017 (US$ Mn)
FIG. 8 Attractive Investment Proposition, by Geography, 2017
FIG. 9 Global Market Positioning of Key BT Manufacturers, 2017
FIG. 10 Global BNT Type A Market, 2016–2026 (US$ Mn)
FIG. 11 Global BNT Type B Market, 2016–2026 (US$ Mn)
FIG. 12 Global BT Market for Neurological Disorders , 2016–2026 (US$ Mn)
FIG. 13 Global BT Market for Cosmetics, 2016–2026 (US$ Mn)
FIG. 14 Global BT Market for Other Therapeutic Areas, 2016–2026 (US$ Mn)
FIG. 15 Global Hospitals Market for BT, 2016–2026 (US$ Mn)
FIG. 16 Global Dermatology & Beauty Clinics Market for BT, 2016–2026 (US$ Mn)
FIG. 17 Global Spas & Cosmetic Centers Market for BT, 2016–2026 (US$ Mn)
FIG. 18 U.S. BT Market, 2016–2026 (US$ Mn)
FIG. 19 Canada BT Market, 2016–2026 (US$ Mn)
FIG. 20 U.K. BT Market, 2016–2026 (US$ Mn)
FIG. 21 Germany BT Market, 2016–2026 (US$ Mn)
FIG. 22 Rest of Europe BT Market, 2016–2026 (US$ Mn)
FIG. 23 Japan BT Market, 2016–2026 (US$ Mn)
FIG. 24 China BT Market, 2016–2026 (US$ Mn)
FIG. 25 Rest of Asia Pacific BT Market, 2016–2026 (US$ Mn)
FIG. 26 Brazil BT Market, 2016–2026 (US$ Mn)
FIG. 27 Mexico BT Market, 2016–2026 (US$ Mn)
FIG. 28 Rest of Latin America BT Market, 2016–2026 (US$ Mn)
FIG. 29 GCC BT Market, 2016–2026 (US$ Mn)
FIG. 30 Rest of Middle East & Africa BT Market, 2016–2026 (US$ Mn)

List of Tables

TABLE 1 Market Snapshot: Global Botulinum Toxin (BT) Market
TABLE 2 Global BT Market, by Product Type, 2016–2026 (US$ Mn)
TABLE 3 Global BT Market, by Application, 2016–2026 (US$ Mn)
TABLE 4 Global BT Market, by End User, 2016–2026 (US$ Mn)
TABLE 5 Global BT Market, by Geography, 2016–2026 (US$ Mn)
TABLE 6 North America BT Market, by Product Type, 2016–2026 (US$ Mn)
TABLE 7 North America BT Market, by Application, 2016–2026 (US$ Mn)
TABLE 8 North America BT Market, by End User, 2016–2026 (US$ Mn)
TABLE 9 North America BT Market, by Country, 2016–2026 (US$ Mn)
TABLE 10 Europe BT Market, by Product Type, 2016–2026 (US$ Mn)
TABLE 11 Europe BT Market, by Application, 2016–2026 (US$ Mn)
TABLE 12 Europe BT Market, by End User, 2016–2026 (US$ Mn)
TABLE 13 Europe BT Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 14 Latin America BT Market, by Product Type, 2016–2026 (US$ Mn)
TABLE 15 Latin America BT Market, by Application, 2016–2026 (US$ Mn)
TABLE 16 Latin America BT Market, by End User, 2016–2026 (US$ Mn)
TABLE 17 Latin America BT Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 18 Asia Pacific BT Market, by Product Type, 2016–2026 (US$ Mn)
TABLE 19 Asia Pacific BT Market, by Product Type, 2016–2026 (US$ Mn)
TABLE 20 Asia Pacific BT Market, by End User, 2016–2026 (US$ Mn)
TABLE 21 Asia Pacific BT Market, by Country/Region, 2016–2026 (US$ Mn)
TABLE 22 Middle East & Africa BT Market, by Product Type, 2016–2026 (US$ Mn)
TABLE 23 Middle East & Africa BT Market, by Application, 2016–2026 (US$ Mn)
TABLE 24 Middle East & Africa BT Market, by End User, 2016–2026 (US$ Mn)
TABLE 25 Middle East & Africa BT Market, by Region, 2016–2026 (US$ Mn)
TABLE 26 Allergan Plc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 27 Speywood Pharmaceuticals: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 28 Merz Pharma GmbH & Co. KGaA: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 29 Elan Pharmaceuticals.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 30 Revance Therapeutics, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 31 Medytox, Inc.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 32 US Worldmed, LLC: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 33 Lanzhou Institute of Biological Products Co.Ltd.: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)
TABLE 34 Ipsen Group: Company Snapshot (Company Overview; Product Portfolio; Financial Information; Key Developments)

Frequently Asked Questions

What is the size of Botulinum Toxin Market?

The market for Botulinum Toxin is expected to reach US$ XX Mn in 2026.

What is the Botulinum Toxin Market CAGR?

The Botulinum Toxin market is expected to see significant CAGR growth over the coming years,at 7.2%.

What is the Forecast period considered for Botulinum Toxin Market?

The report is forecasted from 2018-2026.

What is the base year considered for Botulinum Toxin Market?

The base year of this report is 2017.

Who are the major players in this Market?

Allergan Plc.,Speywood Pharmaceuticals,Merz Pharma GmbH & Co. KGaA,Elan Pharmaceuticals,Revance Therapeutics, Inc. are some of the major players in the global market.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –